Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 55 out of 100. Genetics

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Importance Late-onset Alzheimer disease (AD) is highly heritable. Genome-wide association studies have identified more than 20 AD risk genes. The precise mechanism through which many of these genes are associated with AD remains unknown. Objective To investigate the association of the top 20 AD risk variants with brain amyloidosis. Design, setting, and participants This study analyzed the genetic and florbetapir F 18 data from 322 cognitively normal control individuals, 496 individuals with mild cognitive impairment, and 159 individuals with AD dementia who had genome-wide association studies and 18F-florbetapir positron emission tomographic data from the Alzheimer's Disease Neuroimaging Initiative (ADNI), a prospective, observational, multisite tertiary center clinical and biomarker study. This ongoing study began in 2005. Main outcomes and measures The study tested the association of AD risk allele carrier status (exposure) with florbetapir mean standard uptake value ratio (outcome) using stepwise multivariable linear regression while controlling for age, sex, and apolipoprotein E ε4 genotype. The study also reports on an exploratory 3-dimensional stepwise regression model using an unbiased voxelwise approach in Statistical Parametric Mapping 8 with cluster and significance thresholds at 50 voxels and uncorrected P Results This study included 977 participants (mean [SD] age, 74 [7.5] years; 535 [54.8%] male and 442 [45.2%] female) from the ADNI-1, ADNI-2, and ADNI-Grand Opportunity. The adenosine triphosphate-binding cassette subfamily A member 7 (ABCA7) gene had the strongest association with amyloid deposition (χ2 = 8.38, false discovery rate-corrected P Conclusions and relevance This study found an association of several AD risk variants with brain amyloidosis. The data also suggest that AD genes might differentially regulate AD pathologic findings across the disease stages.

What this study adds

Evidence grade: Low

The record lists 977 participants. This study looked at whether the top 20 known Alzheimer's risk genes are linked to amyloid buildup in the brain, using brain scans from 977 people. Reported effect size: 54.8%; 45.2%.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Apostolova, L. G., Risacher, S. L., Duran, T., Stage, E. C., Goukasian, N., West, J. D., et al. (2018). Associations of the Top 20 Alzheimer Disease Risk Variants With Brain Amyloidosis. JAMA neurology. https://doi.org/10.1001/jamaneurol.2017.4198

Vancouver

Apostolova LG, Risacher SL, Duran T, Stage EC, Goukasian N, West JD, et al. Associations of the Top 20 Alzheimer Disease Risk Variants With Brain Amyloidosis. JAMA neurology. 2018. doi:10.1001/jamaneurol.2017.4198. PMID: 29340569.

BibTeX

@article{apostolova2018-29340569,
  author  = {Apostolova, L. G. and Risacher, S. L. and Duran, T. and Stage, E. C. and Goukasian, N. and West, J. D. and Do, T. M. and Grotts, J. and others},
  title   = {{Associations of the Top 20 Alzheimer Disease Risk Variants With Brain Amyloidosis}},
  journal = {JAMA neurology},
  year    = {2018},
  doi     = {10.1001/jamaneurol.2017.4198},
  pmid    = {29340569},
  url     = {https://doi.org/10.1001/jamaneurol.2017.4198}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

This study looked at whether the top 20 known Alzheimer's risk genes are linked to amyloid buildup in the brain, using brain scans from 977 people. It found that these genes may affect Alzheimer's brain changes in different ways, but the exact mechanism by which most of these genes relate to the disease is still unknown.

Study details

How this study scored 55/100
How this study's score is builtJournal tier 9 of 10; Journal's citation record 2 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 2 of 5; Sample size 2 of 4; Effect reported 2 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 5 of 7; Citations per year 3 of 5; Impact for its field and year 4 of 6; Cited by studies here 2 of 6; Still being cited 2 of 4; Senior author's track record left out, no data; Institution's track record 2 of 3; Multicenter collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. 53 of the 96 points it could be judged on, which is 55 of 100. Total 55 of 100.53 of the 96 points we could judge = 55 of 100

Published in a leading specialty journal. Scored zero for study design and randomized / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 53 of the 96 points we could judge it on, which is 55 out of 100.

ComponentPointsWhy
Journal tier 9 / 10 Tier 2 — leading specialty journal (JAMA neurology)
Journal's citation record 2 / 4 JAMA Neurology: journal h-index 235 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 2 / 5 2018 — within 10 year(s) of the newest study here
Sample size 2 / 4 977 participants
Effect reported 2 / 3 Effect reported as a number, without an interval or test
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 5 / 7 Cited 121 times (OpenAlex, 2026-10-10)
Citations per year 3 / 5 12.1 citations a year over 10 year(s) since 2018
Impact for its field and year 4 / 6 Cited 10.6× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 2 / 6 Cited by 5 other studies in this library
Still being cited 2 / 4 Cited 23 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record — / 4 Senior author's record not available — left out of this score
Institution's track record 2 / 3 University of California, Los Angeles: institution h-index 1,923 (OpenAlex)
Multicenter collaboration 2 / 3 PubMed indexes it as a multicentre study
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 29340569)
Free to read 0 / 2 Behind a paywall — scores zero
Points 53 / 96 Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 53 of the 96 points we could judge it on is 55 out of 100.
Total 55 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 31.

Later studies that cite this one

5 studies in the alzhub library list this one in their references.

Related studies in Genetics from nearby years

Also in Genetics

201 studies in the library are filed under Genetics with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Genetics hub.

Similar studies

More on Genetics

See all studies in Genetics →